Differential response to chemotherapy in metastatic breast cancer in relation to estrogen receptor level. Results of a prospective randomized study

Cancer

Volumn 64, Issue 1, 1989, Pages 6-15

  Rosner, Dutzu ^a   Lane, Warren W ^a   Nemoto, Takuma ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PREDNISONE; VINCRISTINE;

ADVANCED CANCER; BREAST CANCER; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMAN; NEOPLASM METASTASIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RANDOM ALLOCATION; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REMISSION INDUCTION; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0024352358     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19890701)64:1<6::AID-CNCR2820640103>3.0.CO;2-L     Document Type: Article

References (40)

1. Hormone dependency of breast cancer
2. Steroid receptors and other prognostic factors in primary breast cancer
3. Steroid hormone receptors and clinical usefulness in human breast cancer
4. The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer
5. Some comments on the necessity of receptor determination in human breast cancer
6. Relationship between primary breast tumor receptor status and patient survival
7. Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer
8. Influence of estrogen receptor status on response to combination chemotherapy for recurrent breast cancer
9. The correlation of estrogen and progesterone receptor levels with response to chemotherapy for advanced carcinoma of the breast
10. A randomized study of intensive versus moderate chemotherapy programs in metastatic breast cancer
11. Assessment of response to therapy in advanced breast cancer
12. Aggressive Adriamycin‐containing regimen (PM‐FAC) in estrogen receptor‐negative disseminated breast cancer: Results of a Southwest Oncology Group Trial
13. Breast cancer and response to chemotherapy: A possible relationship of hormone receptors and doxorubicin
14. Relationship between estrogen‐receptor proteins and response to chemotherapy in breast cancer
15. Relationship between steroid receptors and response to endocrine therapy and cytotoxic chemotherapy in metastatic breast cancer
16. Correlation of estrogen‐receptor and response to chemotherapy of cyclophosphamide, methetrexate, and 5‐fluorouracil (CMF) in advanced breast cancer
17. Estrogen receptors and response of breast cancer to chemotherapy (Letter to the editor)
18. Estrogen receptor status, doubling time and sensitivity of breast carcinoma cells to adriamycin in tissue culture (Abstr)
19. Estrogen receptors and responsiveness of advanced breast cancer to chemotherapy
20. Chemohormonal therapy in advanced carcinoma of the breast: Cancer and Leukemia Group B Protocol 8081
21. A randomized study of two and three drug regimen in relation with estrogen receptors in metastatic breast cancer (Abstr)
22. Estrogen receptors and responses to combination chemotherapy in metastatic breast cancer: Results of a prospective randomized study
23. Special report: Steroid receptors in breast cancer
24. The relative importance of estrogen receptor analysis as a prognostic factor for recurrence or response to chemotherapy in women with breast cancer
25. Estrogen receptors and response to cytotoxic chemotherapy in advanced breast cancer
26. The variability of estrogen receptors in metastatic breast cancer
27. Changes in multiple or sequential estrogen receptor determinations in breast cancer
28. Estrogen receptor levels in multiple biopsies from patients with breast cancer
29. The relationship between estrogen receptors in primary and secondary breast carcinomas and in sequential primary breast carcinomas
30. Estrogen receptors in bilateral breast cancer
31. Estrogen receptor status and response to chemotherapy in advanced breast cancer
32. Efforts to combine endocrine and chemotherapy in the management of breast cancer: Do two and two equal three?
33. Concurrent or sequential use of cytotoxic chemotherapy and hormone treatment in advanced breast cancer: Report of the Swiss Group for Clinical Research
34. Estrogen receptors and response to chemotherapy in advanced breast cancer
35. Correlation between estrogen‐receptor proteins and response to chemotherapy in patients with breast cancer
36. Estrogen and progesterone receptors as prognostic factors in breast cancer
37. The value of estrogen and progesterone receptors in the treatment of breast cancer
38. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: Findings from National Surgical Adjuvant Breast and Bowel Project Protocol B‐06